ScreenerHero

BCTX BriaCell Therapeutics Corp.

NAS · US · Healthcare · Biotechnology · briacell.com
4.000USD-0.50%Mkt Cap: 34.80M $P/E: —

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap34.80M USD
Enterprise Value11.52M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-30.68M USD
Revenue/Share—
Last Price4.000 USD
Fiscal Year EndJul 2025
MR QuarterApr 2026
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-10.31
PEG—
EV/EBITDA-0.36
EV/Revenue—
P/S—
P/B1.21
EPS (TTM)-0.92
EPS (Forward)-0.39
52W Range
2.60012% of range14.68
52W High14.68 USD
52W Low2.600 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-175.25%
ROA-90.84%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-24.13M USD
CapEx (TTM)456.80K USD
FCF Margin—
FCF Yield-57.59%
Net Debt-22.80M USD
Net Debt/EBITDA0.71
Balance Sheet
Debt/Equity—
Current Ratio7.07
Quick Ratio6.35
Book Value/Sh3.32 USD
Cash/Share2.62 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJan 2, 2020
Splits
Last Split1:10
Split DateAug 25, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.8.70M
Float7.86M
Insiders0.04%
Institutions6.39%
Short Interest
Short Ratio1.4d
Short % Float9.11%
Short % Out.9.11%
Shares Short792.22K
Short (prev mo.)398.91K
Technical
SMA 503.734 (+7.1%)
SMA 2004.214 (-5.1%)
Beta1.51
S&P 52W Chg15.78%
Avg Vol (30d)428.46K
Avg Vol (10d)142.41K
Technical Indicators
RSI (14)51.8
MACD0.1128
MACD Signal0.1313
MACD Hist.-0.0185
BB Upper4.514 USD
BB Middle3.975 USD
BB Lower3.436 USD
BB Width27.12%
ATR (14)0.2669 USD
Vol Ratio (20d)0.66x